| Targeting the microenvironment in solid tumors C Belli, D Trapani, G Viale, P D'Amico, BA Duso, P Della Vigna, F Orsi, ... Cancer treatment reviews 65, 22-32, 2018 | 439 | 2018 |
| Next generation sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer S Morganti, P Tarantino, E Ferraro, P D’Amico, BA Duso, G Curigliano Translational research and onco-omics applications in the era of cancer …, 2019 | 180 | 2019 |
| ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer R Taftaf, X Liu, S Singh, Y Jia, NK Dashzeveg, AD Hoffmann, ... Nature communications 12 (1), 4867, 2021 | 126 | 2021 |
| Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life S Morganti, P Tarantino, E Ferraro, P D’Amico, G Viale, D Trapani, ... Critical reviews in oncology/hematology 133, 171-182, 2019 | 125 | 2019 |
| The evolving landscape of ‘next-generation’immune checkpoint inhibitors: A review L Mazzarella, BA Duso, D Trapani, C Belli, P D'Amico, E Ferraro, G Viale, ... European journal of cancer 117, 14-31, 2019 | 91 | 2019 |
| Circulating tumor cell clusters are frequently detected in women with early-stage breast cancer C Reduzzi, S Di Cosimo, L Gerratana, R Motta, A Martinetti, A Vingiani, ... Cancers 13 (10), 2356, 2021 | 32 | 2021 |
| Role of next-generation sequencing technologies in personalized medicine S Morganti, P Tarantino, E Ferraro, P D’Amico, G Viale, D Trapani, ... P5 eHealth: An Agenda for the Health Technologies of the Future, 125-154, 2020 | 25 | 2020 |
| Liver toxicity in the era of immune checkpoint inhibitors: a practical approach C Belli, M Zuin, L Mazzarella, D Trapani, P D’Amico, E Guerini-Rocco, ... Critical Reviews in Oncology/Hematology 132, 125-129, 2018 | 23 | 2018 |
| Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review D Trapani, F Giugliano, J Uliano, VAA Zia, A Marra, G Viale, E Ferraro, ... Breast cancer research and treatment 187 (2), 323-337, 2021 | 20 | 2021 |
| The use of liquid biopsy in early breast cancer: Clinical evidence and future perspectives P D’Amico, C Corvaja, L Gerratana, C Reduzzi, G Curigliano, ... J. Cancer Metastasis Treat 7 (3), 2021 | 18 | 2021 |
| Unique molecular signatures sustained in circulating monocytes and regulatory T cells in convalescent COVID-19 patients AD Hoffmann, SE Weinberg, S Swaminathan, S Chaudhuri, ... Clinical Immunology 252, 109634, 2023 | 11 | 2023 |
| Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity L Mazzarella, S Giugliano, P D'Amico, C Belli, BA Duso, M Rescigno, ... European Journal of Cancer 141, 218-224, 2020 | 11 | 2020 |
| Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer AN Shah, KJ Carroll, L Gerratana, C Lin, AA Davis, Q Zhang, S Jacob, ... Breast Cancer Research and Treatment 187 (2), 397-405, 2021 | 9 | 2021 |
| Pharmacological management of male breast cancer BA Duso, D Trapani, A Marra, P D’Amico, E Guerini Rocco, N Fusco, ... Expert Opinion on Pharmacotherapy 21 (12), 1493-1504, 2020 | 9 | 2020 |
| Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside AK Abdel-Aziz, MK Saadeldin, P D'Amico, S Orecchioni, F Bertolini, ... European Journal of Cancer 122, 22-41, 2019 | 9 | 2019 |
| Single-cells isolation and molecular analysis: Focus on her2-low CTCs in metastatic breast cancer P D’amico, C Reduzzi, W Qiang, Y Zhang, L Gerratana, Q Zhang, ... Cancers 14 (1), 79, 2021 | 7 | 2021 |
| Dynamic glycoprotein hyposialylation promotes chemotherapy evasion and metastatic seeding of quiescent circulating tumor cell clusters in breast cancer NK Dashzeveg, Y Jia, Y Zhang, L Gerratana, P Patel, A Shajahan, ... Cancer discovery 13 (9), 2050-2071, 2023 | 6 | 2023 |
| Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer AA Davis, L Gerratana, K Clifton, AJ Medford, M Velimirovic, WL Hensing, ... EBioMedicine 86, 2022 | 6 | 2022 |
| Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation? S Morganti, A Marra, E Crimini, P D’Amico, P Zagami, G Curigliano Breast Cancer Research and Treatment 192 (3), 465-484, 2022 | 5 | 2022 |
| Standard of care in hormone receptor–positive metastatic breast cancer: can we improve the current regimens or develop better selection tools? P D'Amico, M Cristofanilli JCO Oncology Practice, 2021 | 5 | 2021 |
